Kos J - Search Results

1

Identification and characterization of the novel reversible and selective cathepsin X inhibitors.

Fonović UP, Mitrović A, Knez D, Jakoš T, Pišlar A, Brus B, Doljak B, Stojan J, Žakelj S, Trontelj J, Gobec S, Kos J. Fonović UP, et al. Among authors: kos j. Sci Rep. 2017 Sep 13;7(1):11459. doi: 10.1038/s41598-017-11935-1. Sci Rep. 2017. PMID: 28904354 Free PMC article.

2

Cathepsin D inactivates cysteine proteinase inhibitors, cystatins.

Lenarcic B, Kos J, Dolenc I, Lucovnik P, Krizaj I, Turk V. Lenarcic B, et al. Among authors: kos j. Biochem Biophys Res Commun. 1988 Jul 29;154(2):765-72. doi: 10.1016/0006-291x(88)90206-9. Biochem Biophys Res Commun. 1988. PMID: 3261170

3

Carboxypeptidase cathepsin X mediates beta2-integrin-dependent adhesion of differentiated U-937 cells.

Obermajer N, Premzl A, Zavasnik Bergant T, Turk B, Kos J. Obermajer N, et al. Among authors: kos j. Exp Cell Res. 2006 Aug 1;312(13):2515-27. doi: 10.1016/j.yexcr.2006.04.019. Epub 2006 May 11. Exp Cell Res. 2006. PMID: 16774752

4

Cysteine cathepsins: regulators of antitumour immune response.

Obermajer N, Doljak B, Kos J. Obermajer N, et al. Among authors: kos j. Expert Opin Biol Ther. 2006 Dec;6(12):1295-309. doi: 10.1517/14712598.6.12.1295. Expert Opin Biol Ther. 2006. PMID: 17223738 Review.

5

Monoclonal antibody to cytokeratin VKIALEVEIATY sequence motif reduces plasminogen activation in breast tumour cells.

Doljak B, Obermajer N, Jamnik P, Kos J. Doljak B, et al. Among authors: kos j. Cancer Lett. 2008 Aug 18;267(1):75-84. doi: 10.1016/j.canlet.2008.03.006. Epub 2008 Apr 22. Cancer Lett. 2008. PMID: 18433993

6

Role of cysteine cathepsins in matrix degradation and cell signalling.

Obermajer N, Jevnikar Z, Doljak B, Kos J. Obermajer N, et al. Among authors: kos j. Connect Tissue Res. 2008;49(3):193-6. doi: 10.1080/03008200802143158. Connect Tissue Res. 2008. PMID: 18661341 Review.

7

Cathepsin X-mediated beta2 integrin activation results in nanotube outgrowth.

Obermajer N, Jevnikar Z, Doljak B, Sadaghiani AM, Bogyo M, Kos J. Obermajer N, et al. Among authors: kos j. Cell Mol Life Sci. 2009 Mar;66(6):1126-34. doi: 10.1007/s00018-009-8829-8. Cell Mol Life Sci. 2009. PMID: 19194656 Free PMC article.

8

Inactivation of harmful tumour-associated proteolysis by nanoparticulate system.

Kos J, Obermajer N, Doljak B, Kocbek P, Kristl J. Kos J, et al. Int J Pharm. 2009 Nov 3;381(2):106-12. doi: 10.1016/j.ijpharm.2009.04.037. Epub 2009 May 5. Int J Pharm. 2009. PMID: 19422896

9

Cathepsin X cleaves the C-terminal dipeptide of alpha- and gamma-enolase and impairs survival and neuritogenesis of neuronal cells.

Obermajer N, Doljak B, Jamnik P, Fonović UP, Kos J. Obermajer N, et al. Among authors: kos j. Int J Biochem Cell Biol. 2009 Aug-Sep;41(8-9):1685-96. doi: 10.1016/j.biocel.2009.02.019. Epub 2009 Mar 6. Int J Biochem Cell Biol. 2009. PMID: 19433310

10

Regulation of cathepsin B activity by 2A2 monoclonal antibody.

Mirković B, Premzl A, Hodnik V, Doljak B, Jevnikar Z, Anderluh G, Kos J. Mirković B, et al. Among authors: kos j. FEBS J. 2009 Sep;276(17):4739-51. doi: 10.1111/j.1742-4658.2009.07171.x. Epub 2009 Jul 27. FEBS J. 2009. PMID: 19656187 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

441 results

Search Page

Filters